secwatch.observer — SEC 8-K summary
======================================

Issuer:     Picard Medical, Inc. (PMI)
CIK:        0002030617
Form:       8-K
Filed at:   2026-01-13T23:59:59+00:00
Accession:  0001829126-26-000265
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Picard Medical publishes investor presentation; expects FDA approval for fully implantable TAH by 2028
--------------------------------------------------------------------------------

- Over 2,100 STAH implants across 27 countries; only FDA-approved total artificial heart.
- Mid-term catalysts: updated BTC label (2Q26), MDR CE-mark (4Q26), NMPA approval (4Q26).
- Next-gen fully implantable TAH (Emperor) may seek FDA approval in 2028; patented.
- U.S. reimbursement under DRG001 (mean ~$297k); market cap ~$123M as of Jan 11, 2026.
- CEO Patrick Schnegelsberg leads team; stock traded $1.63-$13.68 since Aug 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2030617/000182912626000265/0001829126-26-000265-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2030617/000182912626000265/picardmedical_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-26-000265

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer